Nasal foralumab for non-active secondary progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study provides access to an experimental nasal spray medication called foralumab for people with a specific type of MS that has stopped responding to standard treatments. The goal is to see if the drug can slow or stop disability progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed MS diagnosis and are between 25 and 75 years old.
- Your MS is 'non-active secondary progressive' meaning you haven't had relapses for at least 2 years.
- Your disability level is between 2.5 and 7.5 on the EDSS scale.
- You've tried standard MS treatments and your condition has kept getting worse for at least 6 months.
- Your kidneys, liver, and blood counts are within acceptable ranges.
- You are not currently using certain MS medications, corticosteroids, or other drugs listed in the trial rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a nasal spray medication, foralumab, to see if it can help people with non-active secondary progressive multiple sclerosis. It is only for people who completed a previous related study (TILS-021).
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
This study tests a new nasal spray medicine called foralumab to see if it is safe and can slow down ALS. The trial is part of the Healey ALS platform and uses special scans to check how the medicine affects the brain.
This study tests a nasal spray form of the steroid methylprednisolone for treating MS relapses. The goal is to see if this new way of taking the medicine works as well or better than standard treatments.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
Hear when a new Non-Active Secondary Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.